Healthcare provider profile · identity verified

John Yiu, MD

Family Practice · BROOKLYN, NY · NPI 1740440155

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	609	160
Losartan Potassium	Losartan Potassium	450	119
Amlodipine Besylate	Amlodipine Besylate	382	110
Vascepa	Icosapent Ethyl	324	89
Metformin Hcl	Metformin Hcl	262	58
Tamsulosin Hcl	Tamsulosin Hcl	262	66
Metoprolol Succinate	Metoprolol Succinate	162	46
Donepezil Hcl	Donepezil Hcl	143	32
Simvastatin	Simvastatin	138	39
Diclofenac Epolamine	Diclofenac Epolamine	110	48
Omeprazole	Omeprazole	109	51
Finasteride	Finasteride	108	28
Montelukast Sodium	Montelukast Sodium	103	40
Chlorhexidine Gluconate	Chlorhexidine Gluconate	97	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	96	28
Albuterol Sulfate Hfa	Albuterol Sulfate	91	25
Januvia	Sitagliptin Phosphate	91	16
Alendronate Sodium	Alendronate Sodium	89	19
Diclofenac Sodium	Diclofenac Sodium	83	40
Levothyroxine Sodium	Levothyroxine Sodium	77	14
Rosuvastatin Calcium	Rosuvastatin Calcium	77	23
Ammonium Lactate	Ammonium Lactate	76	32
Meloxicam	Meloxicam	75	56
Shingrix	Varicella-Zoster Ge/As01b/Pf	70	35
Meclizine Hcl	Meclizine Hcl	64	52
Farxiga	Dapagliflozin Propanediol	62	13
Jardiance	Empagliflozin	62	12
Raloxifene Hcl	Raloxifene Hcl	58	15
Azithromycin	Azithromycin	53	47
Clopidogrel	Clopidogrel Bisulfate	53	13
Esomeprazole Magnesium	Esomeprazole Magnesium	51	18
Xarelto	Rivaroxaban	47	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	46	suppressed
Glipizide Er	Glipizide	44	12
Janumet	Sitagliptin Phos/Metformin Hcl	44	12
Valsartan	Valsartan	43	15
Eliquis	Apixaban	42	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	41	13
Glipizide	Glipizide	39	suppressed
Fenofibrate	Fenofibrate,micronized	38	13
Gabapentin	Gabapentin	38	21
Zolpidem Tartrate	Zolpidem Tartrate	38	31
Allopurinol	Allopurinol	37	suppressed
Fluticasone Propionate	Fluticasone Propionate	36	21
Hydrochlorothiazide	Hydrochlorothiazide	35	suppressed
Carvedilol	Carvedilol	34	12
Clobetasol Emollient	Clobetasol Propionate/Emoll	34	22
Procto-Med Hc	Hydrocortisone	34	suppressed
Azelastine Hcl	Azelastine Hcl	33	15
Famotidine	Famotidine	33	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	32	16
Linzess	Linaclotide	32	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	30	24
Triamcinolone Acetonide	Triamcinolone Acetonide	30	19
Halobetasol Propionate	Halobetasol Propionate	29	16
Dutasteride	Dutasteride	28	suppressed
Lisinopril	Lisinopril	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	27	suppressed
Enalapril Maleate	Enalapril Maleate	26	suppressed
Hydrocortisone	Hydrocortisone	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	24	suppressed
Trazodone Hcl	Trazodone Hcl	23	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	22	suppressed
Clobetasol Propionate	Clobetasol Propionate	22	13
Ibuprofen	Ibuprofen	22	22
Creon	Lipase/Protease/Amylase	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	14
Glipizide-Metformin	Glipizide/Metformin Hcl	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Prednisone	Prednisone	20	suppressed
Vemlidy	Tenofovir Alafenamide	20	suppressed
Icosapent Ethyl	Icosapent Ethyl	19	11
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Glimepiride	Glimepiride	18	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Rivastigmine	Rivastigmine	18	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Methimazole	Methimazole	17	suppressed
Febuxostat	Febuxostat	16	suppressed
Metformin Er Gastric	Metformin Hcl	16	suppressed
Amoxicillin	Amoxicillin	15	14
Fenofibrate	Fenofibrate	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Jentadueto	Linagliptin/Metformin Hcl	14	suppressed
Loperamide	Loperamide Hcl	14	11
Mometasone Furoate	Mometasone Furoate	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Atenolol	Atenolol	13	suppressed
Colchicine	Colchicine	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Nateglinide	Nateglinide	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Prolia	Denosumab	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Edarbi	Azilsartan Medoxomil	12	suppressed
Furosemide	Furosemide	12	suppressed
Nadolol	Nadolol	12	suppressed
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Xanax	Alprazolam	12	suppressed
Dapagliflozin	Dapagliflozin Propanediol	11	suppressed
Diovan	Valsartan	11	suppressed
Lipitor	Atorvastatin Calcium	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error